Organ cross talk in the critically ill: The heart and kidney

Blood Purification

Volumn 27, Issue 4, 2009, Pages 311-320

  Kociol, Robb ^a   Rogers, Joseph ^b   Shaw, Andrew ^b  

^a DUKE UNIVERSITY HOSPITAL   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Acute decompensated heart failure; Cardiorenal syndrome; Chronic heart failure; Worsening renal function

Indexed keywords

ACETAZOLAMIDE; ADENOSINE RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CALCIUM CHANNEL BLOCKING AGENT; CONIVAPTAN; CREATININE; CYSTATIN C; DIURETIC AGENT; DOBUTAMINE; DOPAMINE; EPLERENONE; FUROSEMIDE; GLYCERYL TRINITRATE; LEVOSIMENDAN; LOOP DIURETIC AGENT; MILRINONE; NATRIURETIC FACTOR; NESIRITIDE; NEUROHORMONE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PLACEBO; ROLOFYLLINE; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TOLVAPTAN; VASOPRESSIN ANTAGONIST;

ACUTE CARDIAC DYSFUNCTION; ACUTE HEART FAILURE; ADD ON THERAPY; CARDIORENAL DYSFUNCTION; CARDIORENAL SYNDROME; CLINICAL TRIAL; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE MARKER; DRUG DOSE ESCALATION; DRUG MEGADOSE; GLOMERULUS FILTRATION RATE; HEART FAILURE; HOMEOSTASIS; HUMAN; HYPERTENSION; HYPOTENSION; IRON BINDING CAPACITY; KIDNEY FAILURE; KIDNEY FUNCTION; LOW DRUG DOSE; MORBIDITY; MORTALITY; NEUROENDOCRINE SYSTEM; OLIGURIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; ULTRAFILTRATION; UNITED STATES; UNSPECIFIED SIDE EFFECT; URINE VOLUME;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CRITICAL ILLNESS; DISEASE MANAGEMENT; FEMALE; HEART DISEASES; HUMANS; KIDNEY DISEASES; MALE;

EID: 61449243779     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000207198     Document Type: Review

References (68)

1. Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, Hailpern SM, Ho M, Howard V, Kissela B, Kittner S, Lloyd-Jones D, McDermott M, Meigs J, Moy C, Nichol G, O'Donnell C, Roger V, Sorlie P, Steinberger J, Thom T, Wilson M, Hong Y; American Heart Association Statistics Committee and Stroke Statistics Subcommittee: Heart disease and stroke statistics - 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008; 117:e25-e146.
2. Heywood JT: The cardiorenal syndrome: lessons from the ADHERE database and treatment options. Heart Fail Rev 2004; 9: 195-201.
3. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R: Cardiorenal syndrome. J Am Coll Cardiol 2008; 52: 1527-1539.
4. Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW: The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 2000; 35: 681-689.
5. Hillege HL, Nitsch D, Pfeffer MA, Swedberg K, McMurray JJ, Yusuf S, Granger CB, Michelson EL, Ostergren J, Cornel JH, de Zeeuw D, Pocock S, van Veldhuisen DJ; Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Investigators: Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 2006; 113: 671-678.
6. Smith GL, Lichtman JH, Bracken MB, Shlipak MG, Phillips CO, DiCapua P, Krumholz HM: Renal impairment and outcomes in heart failure: systematic review and metaanalysis. J Am Coll Cardiol 2006; 47: 1987- 1996.
7. Forman DE, Butler J, Wang Y, Abraham WT, O'Connor CM, Gottlieb SS, Loh E, Massie BM, Rich MW, Stevenson LW, Young JB, Krumholz HM: Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol 2004; 43: 61-67.
8. Butler J, Forman DE, Abraham WT, Gottlieb SS, Loh E, Massie BM, O'Connor CM, Rich MW, Stevenson LW, Wang Y, Young JB, Krumholz HM: Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J 2004; 147: 331-338.
9. Weinfeld MS, Chertow GM, Stevenson LW: Aggravated renal dysfunction during intensive therapy for advanced chronic heart failure. Am Heart J 1999; 138: 285-290.
10. Nohria A, Hasselblad V, Stebbins A, Pauly DF, Fonarow GC, Shah M, Yancy CW, Califf RM, Stevenson LW, Hill JA: Cardiorenal interactions: insights from the ESCAPE trial. J Am Coll Cardiol 2008; 51: 1268-1274.
11. Schrier RW, Abraham WT: Hormones and hemodynamics in heart failure. N Engl J Med 1999; 341: 577-585.
12. Ferguson DW, Berg WJ, Roach PJ, Oren RM, Mark AL: Effects of heart failure on baroreflex control of sympathetic neural activity. Am J Cardiol 1992; 69: 523-531.
13. Weber KT: Aldosterone in congestive heart failure. N Engl J Med 2001; 345: 1689-1697.
14. Schrier RW: Role of diminished renal function in cardiovascular mortality: marker or pathogenetic factor? J Am Coll Cardiol 2006; 47: 1-8.
15. Bongartz LG, Cramer MJ, Doevendans PA, Joles JA, Braam B: The severe cardiorenal syndrome: 'Guyton revisited'. Eur Heart J 2005; 26: 11-17.
16. Levin A: Kidneys, hearts, hormones and immunomodulators: integrated understandings. Blood Purif 2006; 24: 46-50.
17. Virani SA: Management of acute decompensated heart failure: renal implications. Blood Purif 2008; 26: 18-22.
18. Butler J, Geisberg C, Howser R, Portner PM, Rogers JG, Deng MC, Pierson RN 3rd: Relationship between renal function and left ventricular assist device use. Ann Thorac Surg 2006; 81: 1745-1751.
19. Mullens W, Abrahams Z, Skouri HN, Francis GS, Taylor DO, Starling RC, Paganini E, Tang WH: Elevated intra-abdominal pressure in acute decompensated heart failure: a potential contributor to worsening renal function? J Am Coll Cardiol 2008; 51: 300-306.
20. Francis GS, Siegel RM, Goldsmith SR, Olivari MT, Levine TB, Cohn JN: Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis. Ann Intern Med 1985; 103: 1-6.
21. Gottlieb SS, Brater DC, Thomas I, Havranek E, Bourge R, Goldman S, Dyer F, Gomez M, Bennett D, Ticho B, Beckman E, Abraham WT: BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation 2002; 105: 1348-1353.
22. Eshaghian S, Horwich TB, Fonarow GC: Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol 2006; 97: 1759-1764.
23. Kazory A, Ross EA: Contemporary trends in the pharmacological and extracorporeal management of heart failure: a nephrologic perspective. Circulation 2008; 117: 975-983.
24. Wittstein IS: Diuretics; in Baughman KL, Baumgartner WA (eds): Treatment of Advanced Heart Disease. New York, Taylor and Francis, 2006, pp 83-84.
25. Givertz MM, Massie BM, Fields TK, Pearson LL, Dittrich HC; CKI-201 and CKI-202 Investigators: The effects of KW-3902, an adenosine A1-receptor antagonist, on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance. J Am Coll Cardiol 2007; 50: 1551-1560.
26. Rajaram V, Joseph J: Role of adenosine antagonism in the cardio-renal syndrome: pathophysiology and therapeutic potential. Curr Heart Fail Rep 2007; 4: 153-157.
27. Smilde TD, van Veldhuisen DJ, Navis G, Voors AA, Hillege HL: Drawbacks and prognostic value of formulas estimating renal function in patients with chronic heart failure and systolic dysfunction. Circulation 2006; 114: 1572-1580.
28. Koyner JL, Bennett MR, Worcester EM, Ma Q, Raman J, Jeevanandam V, Kasza KE, O'Connor MF, Konczal DJ, Trevino S, Devarajan P, Murray PT: Urinary cystatin C as an early biomarker of acute kidney injury following adult cardiothoracic surgery. Kidney Int 2008; 74: 1059-1069.
29. Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL, Newman AB, Siscovick DS, Stehman-Breen C: Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 2005; 352: 2049-2060.
30. Lassus J, Harjola VP, Sund R, Siirilä-Waris K, Melin J, Peuhkurinen K, Pulkki K, Nieminen MS; for the FINN-AKVA Study group: Prognostic value of cystatin C in acute heart failure in relation to other markers of renal function and NT-proBNP. Eur Heart J 2007; 28: 1841-1847.
31. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A; Acute Kidney Injury Network: Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007; 11:R31.
32. Hirsch R, Dent C, Pfriem H, Allen J, Beekman RH 3rd, Ma Q, Dastrala S, Bennett M, Mitsnefes M, Devarajan P: NGAL is an early predictive biomarker of contrast-induced nephropathy in children. Pediatr Nephrol 2007; 22: 2089-2095.
33. Mishra J, Dent C, Tarabishi R, Mitsnefes MM, Ma Q, Kelly C, Ruff SM, Zahedi K, Shao M, Bean J, Mori K, Barasch J, Devarajan P: Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 2005; 365: 1231-1238.
34. Nickolas TL, O'Rourke MJ, Yang J, Sise ME, Canetta PA, Barasch N, Buchen C, Khan F, Mori K, Giglio J, Devarajan P, Barasch J: Sensitivity and specificity of a single emergency department measurement of urinary neutrophil gelatinase-associated lipocalin for diagnosing acute kidney injury. Ann Intern Med 2008; 148: 810-819.
35. Damman K, van Veldhuisen DJ, Navis G, Voors AA, Hillege HL: Urinary neutrophil gelatinase associated lipocalin (NGAL), a marker of tubular damage, is increased in patients with chronic heart failure. Eur J Heart Fail 2008; 10: 997-1000.
36. Bonventre JV: Kidney Injury Molecule-1 (KIM-1): a specific and sensitive biomarker of kidney injury. Scand J Clin Lab Invest Suppl 2008; 241: 78-83.
37. Han WK, Waikar SS, Johnson A, Betensky RA, Dent CL, Devarajan P, Bonventre JV: Urinary biomarkers in the early diagnosis of acute kidney injury. Kidney Int 2008; 73: 863-869.
38. Channer KS, McLean KA, Lawson-Matthew P, Richardson M: Combination diuretic treatment in severe heart failure: a randomised controlled trial. Br Heart J 1994; 71: 146-150.
39. Javaheri S: Acetazolamide improves central sleep apnea in heart failure: a double-blind, prospective study. Am J Respir Crit Care Med 2006; 173: 234-237.
40. Domanski M, Norman J, Pitt B, Haigney M, Hanlon S, Peyster E; Studies of Left Ventricular Dysfunction: Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 2003; 42: 705-708.
41. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-1321.
42. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717.
43. Dormans TP, van Meyel JJ, Gerlag PG, Tan Y, Russel FG, Smits P: Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion. J Am Coll Cardiol 1996; 28: 376-382.
44. Determining Optimal Dose and Duration of Diuretic Treatment in People With Acute Heart Failure (The DOSE-AHF Study). http://clinicaltrials.gov/ct2/ show/NCT00577135?term=dose+furosemide&rank=1 (accessed 2008).
45. Elkayam U, Ng TM, Hatamizadeh P, Janmohamed M, Mehra A: Renal vasodilatory action of dopamine in patients with heart failure: magnitude of effect and site of action. Circulation 2008; 117: 200-205.
46. Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, Thakkar R, Padley RJ, Põder P, Kivikko M; SURVIVE Investigators: Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA 2007; 297: 1883-1891.
47. Cuffe MS, Califf RM, Adams KF Jr, Benza R, Bourge R, Colucci WS, Massie BM, O'Connor CM, Pina I, Quigg R, Silver MA, Gheorghiade M; Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Investigators: Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 2002; 287: 1541-1547.
48. Felker GM, O'Connor CM: Inotropic therapy for heart failure: an evidence-based approach. Am Heart J 2001; 142: 393-401.
49. Packer M, Carver JR, Rodeheffer RJ, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML, et al: Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 1991; 325: 1468-1475.
50. Colucci WS, Elkayam U, Horton DP, Abraham WT, Bourge RC, Johnson AD, Wagoner LE, Givertz MM, Liang CS, Neibaur M, Haught WH, LeJemtel TH: Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med 2000; 343: 246-253.
51. Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF): Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 2002; 287: 1531-1540.
52. Sackner-Bernstein JD, Skopicki HA, Aaronson KD: Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 2005; 111: 1487-1491.
53. Wang DJ, Dowling TC, Meadows D, Ayala T, Marshall J, Minshall S, Greenberg N, Thattassery E, Fisher ML, Rao K, Gottlieb SS: Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine. Circulation 2004; 110: 1620-1625.
54. Witteles RM, Kao D, Christopherson D, Matsuda K, Vagelos RH, Schreiber D, Fowler MB: Impact of nesiritide on renal function in patients with acute decompensated heart failure and pre-existing renal dysfunction. A randomized, double-blind, placebo-controlled clinical trial. J Am Coll Cardiol 2007; 50: 1835-1840.
55. Yancy CW, Krum H, Massie BM, Silver MA, Stevenson LW, Cheng M, Kim SS, Evans R, for the FUSION II Investigators: Safety and efficacy of outpatient nesiritide in patients with advanced heart failure. Results of the second Follow-Up Serial Infusions Of Nesiritide (FUSION II) trial. Circ Heart Fail 2008; 1: 9-16.
56. Riter HG, Redfield MM, Burnett JC, Chen HH: Nonhypotensive low-dose nesiritide has differential renal effects compared with standard-dose nesiritide in patients with acute decompensated heart failure and renal dysfunction. J Am Coll Cardiol 2006; 47: 2334-2335.
57. Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure. http://clinicaltrials.gov/ct2/show/NCT0047 5852?term= ascend+nesiritide&rank=1 (accessed 2008).
58. Klein L, O'Connor CM, Leimberger JD, Gattis- Stough W, Piña IL, Felker GM, Adams KF Jr, Califf RM, Gheorghiade M; OPTIMECHF Investigators: Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation 2005; 111: 2454-2460.
59. Gheorghiade M, Gattis WA, O'Connor CM, Adams KF Jr, Elkayam U, Barbagelata A, Ghali JK, Benza RL, McGrew FA, Klapholz M, Ouyang J, Orlandi C; Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators: Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 2004; 291: 1963-1971.
60. Gheorghiade M, Konstam MA, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators: Shortterm clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 2007; 297: 1332-1343.
61. Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators: Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007; 297: 1319-1331.
62. Elkayam U, Mehra A, Cohen G, Tummala PP, Karaalp IS, Wani OR, Canetti M: Renal circulatory effects of adenosine in patients with chronic heart failure. J Am Coll Cardiol 1998; 32: 211-215.
63. PROTECT-2: A Study of the Selective A1 Adenosine Receptor Antagonist KW-3902 for Patients Hospitalized With Acute HF and Volume Overload to Assess Treatment Effect on Congestion and Renal Function. http:// clinicaltrials.gov/ ct2/show/NCT00354458? term=PROTECT&rank=38 (accessed 2008).
64. PROTECT-1: A Study of the Selective A1 Adenosine Receptor Antagonist KW-3902 for Patients Hospitalized With Acute HF and Volume Overload to Assess Treatment Effect on Congestion and Renal Function. http:// clinicaltrials.gov/ ct2/show/NCT00328692? term=PROTECT&rank=39 (accessed 2008).
65. Marenzi G, Lauri G, Grazi M, Assanelli E, Campodonico J, Agostoni P: Circulatory response to fluid overload removal by extracorporeal ultrafiltration in refractory congestive heart failure. J Am Coll Cardiol 2001; 38: 963-968.
66. Bart BA, Boyle A, Bank AJ, Anand I, Olivari MT, Kraemer M, Mackedanz S, Sobotka PA, Schollmeyer M, Goldsmith SR: Ultrafiltration versus usual care for hospitalized patients with heart failure: the Relief for Acutely Fluid-Overloaded Patients With Decompensated Congestive Heart Failure (RAPIDCHF) trial. J Am Coll Cardiol 2005; 46: 2043-2046.
67. Costanzo MR, Guglin ME, Saltzberg MT, Jessup ML, Bart BA, Teerlink JR, Jaski BE, Fang JC, Feller ED, Haas GJ, Anderson AS, Schollmeyer MP, Sobotka PA; UNLOAD Trial Investigators: Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 2007; 49: 675-683.
68. Effectiveness of Ultrafiltration in Treating People With Acute Decompensated Heart Failure and Cardiorenal Syndrome (The CARRESS Study). http://clinicaltrials.gov/ ct2/show/NCT00608491?term=carress&ank=1 (accessed 2008).